Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 1652-1657, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holtzman, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holtzman, N. A.

Clinical Chemistry, Vol 40, 1652-1657, Copyright © 1994 by American Association for Clinical Chemistry

Benefits and risks of emerging genetic technologies: the need for regulation

NA Holtzman
Johns Hopkins Medical Institutions, Baltimore, MD 21205-2004.

Efforts to localize human genes to specific chromosomes and then to identify these genes and their role in specific diseases are increasing. These developments will expand the repertoire of genetic tests that are claimed to be predictive of future disease in the person being tested (pre-symptomatic tests) or in future offspring of those being tested (tests for reproductive options). In single-gene (mendelian) disorders, such tests may fail to detect all of the alleles capable of causing disease. In multifactorial disorders, positive results of tests for specific alleles will not always predict future disease because the other necessary factors may be absent. Policies are already in place to provide safe and effective clinical laboratory tests and interventions for subjects with positive test results, and to assure the quality of the laboratories performing such tests, but are not widely known or enforced for genetic tests.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
F. Innocenti and M. J. Ratain
Correspondence re: Raida, M. et al., Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5'-Splice Donor Site of Intron 14 in Patients with Severe 5-Fluorouracil (5-FU)-related Toxicity Compared with Controls. Clin. Cancer Res., 7: 2832-2839, 2001.
Clin. Cancer Res., May 1, 2002; 8(5): 1314 - 1316.
[Full Text] [PDF]

Home page
 Scand J Public HealthHome page
E. Rosen
Genetic information and genetic discrimination how medical records vitiate legal protection: A comparative analysis of international legislation and policies
Scand J Public Health, July 1, 1999; 27(3): 166 - 172.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
N. A. Holtzman
Promoting Safe and Effective Genetic Tests in the United States: Work of the Task Force on Genetic Testing
Clin. Chem., May 1, 1999; 45(5): 732 - 738.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.